AQST Stock Analysis: Buy, Sell, or Hold?
AQST - Aquestive Therapeutics, Inc. Common Stock
$4.66
0.17 (3.67%)
▲
5d:
+9.65%
30d:
+23.61%
90d:
+10.17%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 11, 2026
0d
Get Alerted When AQST Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: AQST shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: AQST shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: AQST is currently trading at $4.66, which is considered extended relative to its 30-day fair value range of $3.74 to $4.32.
Technical Outlook: Technically, AQST is in a strong uptrend. The price is approaching resistance at $4.75. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.7% recently.
Market Sentiment: AQST scores 5/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $9.33 (+100.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, AQST is in a strong uptrend. The price is approaching resistance at $4.75. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.7% recently.
Market Sentiment: AQST scores 5/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $9.33 (+100.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$3.74 -
$4.32
Company Quality Score
35/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
26.3%
All Signals
- BEARISH: Price extended above range (+7.9% above its trading range)
- BEARISH: Weak technical setup (5/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.7%)
- BULLISH: Trading 100.3% below Wall St target ($9.33)
- WARNING: Composite score 35/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$3.74 -
$4.32
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$4.02
Resistance Level
$4.75
Current Trend
Strong Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-8.18
Wall Street Target
$9.33
(+100.3%)
Revenue Growth (YoY)
38.1%
Profit Margin
-144.6%
Share & Embed Analysis
Last updated: August 24, 2026 12:38 AM ET
Data refreshes hourly during market hours. Next update: 1:38 AM
Data refreshes hourly during market hours. Next update: 1:38 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AQST showing a specific setup today?
Insider Activity (6 Months)
0
Buys
7
Sells
Net
INSIDERS SELLING
Recent Transactions
A Ernest Toth Jr
SELL
58254 shares
2026-03-10
Cassie Jung
SELL
45791 shares
2026-03-10
Daniel Barber
SELL
180677 shares
2026-03-10
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$212 | 67 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$107 | 56 HOLD |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$101 | 43 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$664 | 48 HOLD |
|
LQDA
Liquidia Technologies Inc |
STRONG BUY
10 analysts |
$108 | 55 HOLD |
